Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-58M

41M

Verkoop

-61M

711M

K/W

Sectorgemiddelde

51.957

64.641

EPS

1.06

Dividendrendement

0.25

Winstmarge

5.726

Werknemers

11,000

EBITDA

-38M

180M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-5.15% downside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

0.25%

2.31%

Volgende Winsten

4 aug 2026

Volgende dividenddatum

7 aug 2026

Volgende Ex Dividend datum

23 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4B

12B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

16%

84%

29 / 340 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 19:44 UTC

News

Revvity Inc shares are higher ahead of tomorrow's earnings report, with analysts projecting a 3.9% revenue growth year-on-year, recovering from last year's decline.

31 jul 2026, 19:16 UTC

Revvity Inc shares are lower today amid broader market declines, influenced by rising yields and inflation concerns following a significant increase in crude oil prices.

29 jul 2026, 20:08 UTC

Revvity Inc shares are higher today, reflecting a steady upward trend amid rising oil prices and broader market influences. The stock is near its one-month range high.

28 jul 2026, 20:03 UTC

Revvity Inc shares are higher during Tuesday's session, continuing their advance since Monday's close, despite broader market weakness in Asian indices.

27 jul 2026, 21:02 UTC

Revvity Inc shares are lower in after-market hours, continuing a downward trend with three consecutive daily declines. No specific news was identified for the movement.

22 jul 2026, 18:51 UTC

Revvity Inc shares are higher since Tuesday's close amid broader market gains, influenced by rising crude oil prices from geopolitical tensions involving the U.S. and Iran.

21 jul 2026, 20:02 UTC

Revvity Inc shares are higher, supported by renewed interest in AI stocks and anticipation of earnings from major companies like Alphabet and Tesla.

20 jul 2026, 19:21 UTC

News

Revvity Inc. published its 2026 Impact Report, disclosing Scope 3 emissions. Shares are lower amid broader industry challenges and a cautious analyst outlook.

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

-5.15% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 109.29 USD  -5.15%

Hoogste 130 USD

Laagste 90 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

3

Buy

8

Hold

0

Sell

Sentiment

By Acuity

29 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat